Lixte Biotechnology Raises $1.5M in Preferred Stock Sale
Ticker: LIXT · Form: 8-K · Filed: Jul 11, 2025 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 8-K |
| Filed Date | Jul 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, preferred-stock, warrants, r&d
Related Tickers: LIXT
TL;DR
Lixte Biotech just raised $1.5M via preferred stock and warrants to fund R&D.
AI Summary
Lixte Biotechnology Holdings, Inc. announced on July 11, 2025, that it entered into a securities purchase agreement on July 9, 2025. This agreement involves the sale of approximately $1.5 million of its Series B Convertible Preferred Stock and warrants to purchase common stock. The company intends to use the net proceeds for general corporate purposes, including research and development and working capital.
Why It Matters
This capital raise provides Lixte Biotechnology with funds to advance its research and development efforts, potentially leading to new therapeutic advancements.
Risk Assessment
Risk Level: medium — The company is raising capital through preferred stock and warrants, which can be dilutive to common shareholders and indicates a need for funding to support operations and development.
Key Numbers
- $1.5M — Capital Raised (Through sale of Series B Convertible Preferred Stock and warrants.)
Key Players & Entities
- Lixte Biotechnology Holdings, Inc. (company) — Registrant
- July 11, 2025 (date) — Report Date
- July 9, 2025 (date) — Date of Securities Purchase Agreement
- $1.5 million (dollar_amount) — Amount of Series B Convertible Preferred Stock sold
FAQ
What is the specific conversion price for the Series B Convertible Preferred Stock?
The filing does not specify the conversion price for the Series B Convertible Preferred Stock.
What are the terms of the warrants issued alongside the preferred stock?
The filing mentions warrants to purchase common stock but does not detail their specific terms, exercise price, or expiration date.
Who are the purchasers in this securities purchase agreement?
The filing does not identify the specific purchasers involved in the securities purchase agreement.
What is the intended use of the net proceeds from this offering?
The net proceeds are intended for general corporate purposes, including research and development and working capital.
What is the par value per share for the common stock and warrants?
The par value for LIXT:CommonStockParValue0.0001PerShareMember and LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember is $0.0001 per share.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 11, 2025 regarding LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).